NAVLIN Daily NewsCheckout Today’s News
Last week, NAVLIN Daily brought you key market access developments from across the globeIn the U.S., President Donald Trump is expected to announce new MFN drug pricing deals in the coming days. Reportedly, the deals will include commitments to offer MFN pricing to state Medicaid programs, potentially increasing manufacturer participation in CMS’ voluntary GENEROUS modelMeanwhile, the CDA issued new guidance on using AI-generated real-world evidence in HTA submissions, and China updated its Disease-Based Payment reimbursement scheme to include 158 primary care conditions
NICE has confirmed it is adopting the UK EQ-5D-5L value set, following a consultation The EQ-5D-5L value set reflects more recent research into societal preferences as a basis for the QALY calculations that underpin NICE’s cost-effectiveness assessmentsAn ABPI impact assessment of 71 technology appraisals found that cancer treatments extending life tend to become more cost-effective under the new value set, while treatments that improve quality of life without extending it may become less so, with implications for patient access
The U.S. White House is expected to announce new Most Favored Nation (MFN) drug pricing agreements with several midsized biotechnology companies on Monday, according to reports from BloombergThe outlet notes that the deals will include commitments to offer MFN pricing to state Medicaid programs, potentially increasing manufacturer participation in CMS’ voluntary GENEROUS modelThe announcements will be closely watched for signs that the administration has adjusted its MFN approach to address concerns from midsized drugmakers, many of which have been reluctant to participate in existing pricing initiatives
China’s former NHSA official, Xiong Xianjun, said the “impossible trio” – or the infeasible coexistence of high-priced innovative drugs, insurance fund sustainability, and patient access – is a mythHe sees national insurance price negotiations in terms of basic economics, with win-win transactions possible even for expensive new drugsThe former director added that the Commercial Insurance Innovative Drug List helps innovative drugs enter hospitals, but full implementation requires the development of a seamless system to tie public and private insurance and expand commercial insurance premium pools
The U.S. Department of Health and Human Services (HHS) recently published a Request for Information (RFI) soliciting public feedback on federal vaccine recommendationsThe agency is looking for comments on the categories used in federal vaccine recommendations, including routine (universal), risk-based, and shared clinical decision makingComments in response to the RFI must be submitted by September 20, 2026
Last week, NAVLIN Daily brought you key market access developments from across the globe In the U.S., nine major PBMs moved to integrate TrumpRx cash prices into benefit tools, while a new BLS report found that prescription drug prices fell 3.1% from July 2025 to July 2026, their sharpest annual decline in more than 60 years In Japan, a health ministry-funded research group broadly agreed on its technical review of the CEA system
Following China's latest VBP round in July, PhIRDA reports that the system now favors big players more heavily. Hospitals can specify brand preferences, and revival bids can benefit original brands and leading genericsAt the same time, some manufacturers continue to cut prices by 80% to stay competitive, disrupting markets and straining anti-involution effortsIncreasingly complicated rules, with anchors and weight systems, aim to balance needs but risk overshadowing core VBP goals, leaving policymakers with lingering hurdles
Sales of generic GLP-1 injectable drugs in India reached Rs 460 million ($4.81 million, at the time of publishing) by July 2026, with volume rising to 192,000 units, according to India Ratings and Research (Ind-Ra)The segment has expanded since generic versions became available following the expiry of semaglutide’s patent in March, with lower-priced alternatives supporting increased uptake These products are priced 50% to 75% below branded products such as Ozempic (semaglutide) and Wegovy (semaglutide)
Germany's Federal Joint Committee (G-BA) could not consider the final Joint Clinical Assessment (JCA) report for Ojemda because it had not been published when the German benefit assessment began, although the JCA dossier formed part of the evidence reviewedG-BA rejected Ipsen's matching-adjusted indirect comparison (MAIC) from the JCA dossier for the German benefit assessment and instead based its assessment primarily on the single-arm FIREFLY-1 study, using a newer three-year data cutAs an orphan drug, Ojemda underwent Germany's abbreviated assessment procedure; if annual sales exceed EUR 30 million, it will become subject to a standard benefit assessment
A Japanese health ministry-funded research group has broadly approved its draft conclusions on technical reforms to the country’s cost-effectiveness assessment (CEA) systemThe group called for greater opportunities for manufacturers to attend CEA organization meetings and better use of an existing mechanism for considering important new evidenceA final report is expected to be submitted to the Central Social Insurance Medical Council (Chuikyo) in September, although industry representatives have called for further technical discussions
650+
+99%
<24
4,000+
24x7
99.5%
